R P DeMatteo

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
    Vinod P Balachandran
    Department of Surgery, Memorial Hospital, New York, New York, USA
    Nat Med 17:1094-100. 2011
  2. pmc Toll-like receptor 9 inhibition reduces mortality in polymicrobial sepsis
    George Plitas
    Hepatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Exp Med 205:1277-83. 2008
  3. pmc SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors
    Antoine Italiano
    Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    BMC Cancer 12:408. 2012
  4. pmc Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract
    George Miller
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Clin Cancer Res 28:62. 2009
  5. ncbi request reprint Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 112:608-15. 2008
  6. ncbi request reprint The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571)
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 9:831-9. 2002
  7. pmc Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 245:347-52. 2007
  8. ncbi request reprint Management of primary liver sarcomas
    Juürgen Weitz
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 109:1391-6. 2007
  9. ncbi request reprint Treatment of advanced gastrointestinal stromal tumor: a marriage of targeted therapy and surgery?
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10021, USA
    Ann Surg Oncol 14:1-2. 2007
  10. ncbi request reprint Recent advances in hepatic resection
    R P DeMatteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Semin Surg Oncol 19:200-7. 2000

Research Grants

  1. STI571 Therapy for Gastrointestinal Stromal Tumors
    Ronald DeMatteo; Fiscal Year: 2002
  2. Natural Killer Dendritic Cells in Listeria Infection
    Ronald DeMatteo; Fiscal Year: 2007

Detail Information

Publications110 found, 100 shown here

  1. pmc Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
    Vinod P Balachandran
    Department of Surgery, Memorial Hospital, New York, New York, USA
    Nat Med 17:1094-100. 2011
    ..Thus, T cells are crucial to the antitumor effects of imatinib in GIST, and concomitant immunotherapy may further improve outcomes in human cancers treated with targeted agents...
  2. pmc Toll-like receptor 9 inhibition reduces mortality in polymicrobial sepsis
    George Plitas
    Hepatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Exp Med 205:1277-83. 2008
    ..Our findings demonstrate that the detrimental immune response to bacterial sepsis occurs via TLR9 stimulation. TLR9 blockade is a potential strategy for the treatment of human sepsis...
  3. pmc SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors
    Antoine Italiano
    Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    BMC Cancer 12:408. 2012
    ..A recent report identified four non-syndromic, KIT/PDGFRA WT GIST harboring compound heterozygous or homozygous mutations in SDHA encoding the main subunit of the SDH complex II...
  4. pmc Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract
    George Miller
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Clin Cancer Res 28:62. 2009
    ..The pathogenesis of biliary cancers is ill-defined. This study investigates changes in gene expression and copy number in biliary cancers and correlates these changes with anatomical site of origin, histopathology and outcome...
  5. ncbi request reprint Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 112:608-15. 2008
    ..Although the efficacy of tyrosine kinase inhibitors in metastatic GIST depends on tumor mutation status, there have been conflicting reports on the prognostic importance of KIT mutation in primary GIST...
  6. ncbi request reprint The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571)
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 9:831-9. 2002
    ..Although STI571 was first applied to GIST only 2 years ago, it has already revolutionized the treatment of patients with metastatic disease and is also currently being tested as an adjuvant therapy after the resection of primary GIST...
  7. pmc Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 245:347-52. 2007
    ..Nearly all tumors have an activating mutation in the KIT or, less often, PDGFRalpha, gene. Therapy with tyrosine kinase inhibitors benefits over 80% of patients with advanced GIST, but most patients eventually develop drug resistance...
  8. ncbi request reprint Management of primary liver sarcomas
    Juürgen Weitz
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 109:1391-6. 2007
    ..Primary hepatic sarcoma is a rare entity. The objectives of the study were to define treatment and long-term outcome and to identify prognostic factors...
  9. ncbi request reprint Treatment of advanced gastrointestinal stromal tumor: a marriage of targeted therapy and surgery?
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10021, USA
    Ann Surg Oncol 14:1-2. 2007
  10. ncbi request reprint Recent advances in hepatic resection
    R P DeMatteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Semin Surg Oncol 19:200-7. 2000
    ..We present a summary of our experience with these advances...
  11. ncbi request reprint A little teaching point for the fellows
    Ronald P Dematteo
    Hepatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Surgery 138:959-60. 2005
  12. pmc Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma
    W R Jarnagin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg 234:507-17; discussion 517-9. 2001
    ..To analyze resectability and survival in patients with hilar cholangiocarcinoma according to a proposed preoperative staging scheme that fully integrates local, tumor-related factors...
  13. doi request reprint Hepatic arterial nodal metastases in pancreatic cancer: is this the node of importance?
    J LaFemina
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Gastrointest Surg 17:1092-7. 2013
    ..The objectives of this study were to describe the prognostic significance of HALN metastases and to assess the predictive performance of HALN compared to peripancreatic lymph node status...
  14. ncbi request reprint A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases
    W R Jarnagin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 91:1121-8. 2001
    ....
  15. ncbi request reprint Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature
    Sonam Prakash
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Pediatr Hematol Oncol 27:179-87. 2005
    ..The distinct gene expression profile suggests avenues for investigation of pathogenesis and potential therapeutic strategies...
  16. doi request reprint Perioperative complications influence recurrence and survival after resection of hepatic colorectal metastases
    C Correa-Gallego
    Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 20:2477-84. 2013
    ..Perioperative outcomes, such as blood loss, transfusions, and morbidity, have been linked to cancer-specific survival, but this is largely unsupported by prospective data...
  17. doi request reprint Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease
    K A Bickenbach
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, USA
    Ann Surg Oncol 19:1663-9. 2012
    ..The objective of this study was to evaluate outcome of initially unresectable patients who respond to multimodality therapy and undergo resection...
  18. ncbi request reprint Caudate hepatectomy for cancer: a single institution experience with 150 patients
    William G Hawkins
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Coll Surg 200:345-52. 2005
    ..Our objective was to assess our results with resection of the caudate lobe of the liver for malignant disease...
  19. ncbi request reprint Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors
    Narasimhan P Agaram
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:170-81. 2007
    ..Our goal was to investigate the spectrum of pathologic response and molecular alterations in a group of GIST patients, clinically defined as having imatinib-stable/imatinib-responsive lesions, who underwent surgical resection...
  20. doi request reprint Malignant progression in IPMN: a cohort analysis of patients initially selected for resection or observation
    J LaFemina
    Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 20:440-7. 2013
    ..The relative risk of carcinoma in regions remote from the radiographically identified cyst remains poorly defined. This study describes the natural history of IPMN in patients initially selected for resection or surveillance...
  21. pmc Results of hepatic resection for sarcoma metastatic to liver
    R P DeMatteo
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg 234:540-7; discussion 547-8. 2001
    ..Hepatectomy should be considered when complete gross resection is possible, especially when the time to the development of liver metastasis exceeds 2 years...
  22. ncbi request reprint Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes
    S M Weber
    Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    J Am Coll Surg 193:384-91. 2001
    ..Although complete resection improved survival, recurrence was common. The majority of recurrences were local or regional, which may help guide future adjuvant therapy strategies...
  23. pmc Perihepatic lymph node assessment in patients undergoing partial hepatectomy for malignancy
    Stephen R Grobmyer
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 244:260-4. 2006
    ..To assess the value of preoperative imaging studies and the intraoperative assessment of perihepatic lymph nodes in patients undergoing partial hepatectomy for malignancy...
  24. doi request reprint Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma
    Steven C Katz
    Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Ann Surg 249:617-23. 2009
    ..To determine if the degree of blood loss during resection of hepatocellular carcinoma (HCC) is predictive of recurrence and long-term survival...
  25. ncbi request reprint Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy
    Peter Kornprat
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Ann Surg Oncol 14:1151-60. 2007
    ..Despite an unknown benefit, hepatic resection is playing an increasing role in patients with extensive disease...
  26. ncbi request reprint Clinical management of gastrointestinal stromal tumors: before and after STI-571
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hum Pathol 33:466-77. 2002
    ..The advent of STI-571 has markedly altered the clinical approach to GIST. It has proven to be effective in metastatic GIST and is also under investigation as a neoadjuvant and adjuvant therapy...
  27. ncbi request reprint The role of adjuvant therapy after liver resection for colorectal cancer metastases
    L Ruo
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Clin Colorectal Cancer 1:154-66; discussion 167-8. 2001
    ..Identification of subgroups through clinical features, molecular markers, proteins, or specific tumor properties may also help to individualize treatment...
  28. doi request reprint Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma
    Itaru Endo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Ann Surg Oncol 15:2104-12. 2008
    ..Frozen section analysis of bile duct margins is often used to guide the extent of surgical resection for hilar cholangiocarcinoma (HCCA), but the usefulness of this practice is unknown...
  29. ncbi request reprint Downstaging in pancreatic cancer: A matched analysis of patients resected following systemic treatment of initially locally unresectable disease
    K A Bickenbach
    Memorial Sloan Kettering Cancer Center, New York, NY Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 29:257. 2011
    ..Standard treatment for these patients is systemic therapy with or without radiation. The objective of this study was to evaluate outcome of patients who respond to this treatment and undergo resection...
  30. ncbi request reprint Hepatic arterial infusional (HAI) therapy in patients with unresectable primary liver cancer: Use of dynamic contrast enhanced MRI to evaluate response
    W R Jarnagin
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 26:4597. 2008
    ....
  31. doi request reprint Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC)
    A Duffy
    Department of Medicine, Memorial Sloan Kettering Cancer Center MSKCC, New York, NY 10021, USA
    J Surg Oncol 98:485-9. 2008
    ..The incidence of gallbladder cancer (GBC) in the US is 1.2/100,000. This report examines the patterns of presentation, adjuvant treatment and survival of a large cohort of patients with GBC evaluated at MSKCC over a 10-year period...
  32. ncbi request reprint What is the yield of intraoperative ultrasonography during partial hepatectomy for malignant disease?
    W R Jarnagin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Coll Surg 192:577-83. 2001
    ..This study was undertaken to reassess the yield of IOUS in light of recent improvements in preoperative staging...
  33. pmc Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors
    Narasimhan P Agaram
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Genes Chromosomes Cancer 47:853-9. 2008
    ..A secondary V600E BRAF mutation could represent an alternative mechanism of imatinib resistance. Kinase inhibitors targeting BRAF may be effective therapeutic options in this molecular GIST subset...
  34. pmc Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance
    Tianhua Guo
    Departments of Pathology, Medicine, and Surgery, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, NY 10021, USA
    Clin Cancer Res 15:6862-70. 2009
    ..The clinical benefit of sunitinib is genotype-dependent in regards to both primary and secondary mutations, with GIST patients harboring the KIT(AY502-3ins) exon 9 mutation being the most sensitive...
  35. pmc Combined surgical and molecular therapy: the gastrointestinal stromal tumor model
    Jason S Gold
    Hepatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 244:176-84. 2006
    ..The integration of surgery and treatment with targeted molecular agents in the treatment of GIST is highlighted...
  36. ncbi request reprint Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor
    Tianhua Guo
    Department of Pathology, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Clin Cancer Res 13:4874-81. 2007
    ....
  37. ncbi request reprint 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer
    Carlos U Corvera
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Coll Surg 206:57-65. 2008
    ..The role of PET in detecting disease recurrence after resection was also examined...
  38. pmc Molecular characterization of pediatric gastrointestinal stromal tumors
    Narasimhan P Agaram
    Department of Pathology, Sloan Kettering Institute, New York, New York 10021, USA
    Clin Cancer Res 14:3204-15. 2008
    ....
  39. ncbi request reprint Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor
    Ronald P Dematteo
    Hepatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Curr Probl Surg 40:144-93. 2003
  40. ncbi request reprint Survival after resection of liver metastases from colorectal cancer with poor clinical risk factors using adjuvant systemic plus hepatic arterial therapy
    N E Kemeny
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 26:4076. 2008
    ..In 2 different CRS methodologies, 5 year survival is 14-25% in pts with 3-5 points (Fong Y: Ann Surg 1999, Nordlinger B: Cancer 1996)...
  41. ncbi request reprint Adequate lymph node assessment for extrahepatic bile duct cancer: Do the data support the current AJCC recommendations?
    K Ito
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 27:4576. 2009
    ..We hypothesize that this recommendation is insufficient and will lead to underestimation of N stage of EHBDCA...
  42. ncbi request reprint Intraductal papillary neoplasm of the bile duct (IPNB): A biliary equivalent to IPMN of the pancreas?
    F G Rocha
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 29:201. 2011
    ..This study examines the incidence, clinicopathologic features and outcome of IPNB in a single center...
  43. ncbi request reprint Expression of the c-met and HGF in resected hepatocellular carcinoma (rHCC): Correlation with clinicopathological features (CP) and overall survival (OS)
    F D Huitzil
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 26:4599. 2008
    ..We determined c-met and HGF mRNA expression in tumor (T) and non-tumoral tissue (NT) in patients (pts) with rHCC; and studied correlation of their expression with CP and OS...
  44. ncbi request reprint Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis
    R R White
    Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Gastrointest Surg 11:256-63. 2007
    ..The purpose of this study was to compare rates and patterns of disease progression following percutaneous, image-guided radiofrequency ablation (RFA) and nonanatomic wedge resection for solitary colorectal liver metastases...
  45. doi request reprint Synchronous hepatic metastases from colon cancer: changing treatment strategies and results of surgical intervention
    Bridget N Fahy
    Department of Surgery, The Methodist Hospital, Houston, TX 77030, USA
    Ann Surg Oncol 16:361-70. 2009
    ..A multidisciplinary treatment approach which combines both medical and surgical modalities may be associated with improved survival...
  46. doi request reprint Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer
    Hiromichi Ito
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Ann Surg 247:994-1002. 2008
    ..The objective of this study was to evaluate the impact of postoperative morbidity on the long-term outcome after liver resection for MCRC...
  47. ncbi request reprint Predictors and patterns of recurrence after resection of hepatocellular carcinoma
    Charles Cha
    Hepatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Am Coll Surg 197:753-8. 2003
    ..The objectives of this study were to determine the risk factors for recurrence of HCC after hepatectomy and to examine the outcomes once tumor recurrence occurs...
  48. ncbi request reprint Role of intraoperative thermoablation combined with resection in the treatment of hepatic metastasis from colorectal cancer
    Peter Kornprat
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Arch Surg 142:1087-92. 2007
    ..Thermoablation, either cryosurgical ablation (CSA) or radiofrequency ablation (RFA), combined with resection is effective in the treatment of extensive bilobar colorectal metastasis...
  49. ncbi request reprint Diabetes is associated with increased perioperative mortality but equivalent long-term outcome after hepatic resection for colorectal cancer
    Sarah A Little
    Department of Surgery, Hepatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Gastrointest Surg 6:88-94. 2002
    ..We conclude that the presence of diabetes is associated with a higher incidence of perioperative mortality. In patients with diabetes mellitus and parenchymal steatosis, major hepatic resection should be undertaken with caution...
  50. pmc Long-term outcomes following microwave ablation for liver malignancies
    U Leung
    Departments of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Br J Surg 102:85-91. 2015
    ..Microwave ablation has emerged as a promising treatment for liver malignancies, but there are scant long-term follow-up data. This study evaluated long-term outcomes, with a comparison of 915-MHz and 2.4-GHz ablation systems...
  51. ncbi request reprint Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison
    B M Clary
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 8:290-9. 2001
    ..The pattern of distant spread follows the known patterns of hematogenous dissemination. Complete surgical resection is the cornerstone of treatment for primary GIST and LMS and in selected patients with local and distant recurrence...
  52. ncbi request reprint Peritoneal washings are not predictive of occult peritoneal disease in patients with hilar cholangiocarcinoma
    R C Martin
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Am Coll Surg 193:620-5. 2001
    ..There was no association between percutaneous transhepatic biliary drainage and peritoneal tumor seeding...
  53. ncbi request reprint The role of staging laparoscopy in hepatobiliary malignancy: prospective analysis of 401 cases
    M D'Angelica
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 10:183-9. 2003
    ..Patients with potentially resectable hepatobiliary malignancy are frequently found to have unresectable tumors at laparotomy. We prospectively evaluated staging laparoscopy in patients with resectable disease on preoperative imaging...
  54. doi request reprint A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma
    Clifford S Cho
    Hepatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Am Coll Surg 206:281-91. 2008
    ..Numerous staging systems have been devised for purposes of risk classification; we sought to identify the optimal staging system to predict postoperative survival...
  55. doi request reprint Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma
    Kaori Ito
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Surg 251:675-81. 2010
    ..To examine the importance of adequate lymph node sampling in staging of extrahepatic bile duct cancer (EHBDCA)...
  56. pmc Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases
    David A Kooby
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg 237:860-9; discussion 869-70. 2003
    ..To determine if transfusion affected perioperative and long-term outcome in patients undergoing liver resection for metastatic colorectal cancer...
  57. doi request reprint Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection
    Itaru Endo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 248:84-96. 2008
    ..This study analyzes changes in IHC frequency, demographics, and treatment outcome in a consecutive and single institutional cohort...
  58. ncbi request reprint Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma
    Kui Hin Liau
    Hepatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:1948-55. 2005
    ..Surgical resection for large (> 10 cm) hepatocellular carcinoma (HCC) is believed by many to be ineffective. The objective of the current study was to review the outcome of partial hepatectomy in patients with large HCC...
  59. doi request reprint Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma
    Shishir K Maithel
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Surg Oncol 15:3512-20. 2008
    ..Factors associated with the likelihood of subradiographic unresectable disease have not been clearly defined...
  60. ncbi request reprint Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: trends in treatment over time in 440 patients
    Jason S Gold
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg 247:109-17. 2008
    ..We aimed to assess the evolution of the technical approach over time and correlations with morbidity, mortality, and oncologic outcome...
  61. ncbi request reprint Comparative ultrastructural analysis and KIT/PDGFRA genotype in 125 gastrointestinal stromal tumors
    Narasimhan P Agaram
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ultrastruct Pathol 30:443-52. 2006
    ..GISTs showing both NS-G and microtubules were associated with KIT exon 11 genotype and spindle cell morphology. PDGFRA mutated cases were associated with gastric location, predominantly epithelioid morphology and lacked NS-G...
  62. ncbi request reprint Gastrointestinal stromal tumor: 5 years later
    Sanne M van der Zwan
    Hepatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:1781-8. 2005
    ..The integration of surgery and molecular therapy in GIST will serve as a prototype for the management of other solid tumors for which targeted agents become available...
  63. ncbi request reprint Surgical therapy for metastatic disease to the liver
    David J Bentrem
    Hepatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Annu Rev Med 56:139-56. 2005
    ..The indications for surgical treatment of liver metastases are broadening as a variety of novel therapies are being developed, including hepatic artery embolization, hepatic artery infusion of chemotherapy, and radiofrequency ablation...
  64. ncbi request reprint Use of CXCR4 as a prognostic marker for disease-specific survival and pattern of recurrence following resection of hepatic colorectal metastases
    A C Yopp
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 27:11081. 2009
    ..This study examines the relationship between tumor chemokine receptor expression, pattern of recurrence and outcome after resection of hepatic metastases...
  65. ncbi request reprint Phase II single-arm, single-institution trial of neoadjuvant gemcitabine and oxaliplatin treatment (NT) in patients (pts) with resectable pancreas adenocarcinoma (PC)
    E M O'Reilly
    Memorial Sloan Kettering Cancer Center, New York, NY Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 29:4065. 2011
    ..NT offers higher likelihood of systemic therapy delivery to all Pts. We conducted a single institution (MSKCC), phase II trial of NT in Pts with resectable PC to assess 18-month survival rate...
  66. pmc Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram
    B Groot Koerkamp
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA Department of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam
    Ann Oncol 26:1930-5. 2015
    ..The objective of this study was to derive and validate a prognostic nomogram to predict disease-specific survival (DSS) after a curative intent resection of perihilar cholangiocarcinoma (PHC)...
  67. ncbi request reprint Management of 155 patients with benign liver tumours
    C K Charny
    Department of Surgery, New York Presbyterian Hospital-Cornell Campus, New York, NY, USA
    Br J Surg 88:808-13. 2001
    ..Symptomatic patients with a small FNH or haemangioma can be observed because their symptoms are unlikely to be related to the liver tumour. Percutaneous needle biopsy rarely changes management...
  68. ncbi request reprint Actual 10-year survival after resection of colorectal liver metastases defines cure
    James S Tomlinson
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:4575-80. 2007
    ..There is now sufficient follow-up on a significant number of patients to address the curative intent of resecting CLM...
  69. pmc Multidisciplinary treatment of gastrointestinal stromal tumors
    T Peter Kingham
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 303 E 60th Street, Apt 28E, NY, NY 10022, USA
    Surg Clin North Am 89:217-33, x. 2009
    ..Diagnosing and treating GIST requires a multidisciplinary approach, given the combination of pathologic and radiographic evaluation, surgical treatment, and oncologic care required to successfully treat patients with GIST...
  70. pmc Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
    Ronald P Dematteo
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet 373:1097-104. 2009
    ..We postulated that adjuvant treatment with imatinib would improve recurrence-free survival compared with placebo after resection of localised, primary gastrointestinal stromal tumour...
  71. pmc Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation
    Charles H Cha
    Hepatobiliary Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg 238:315-21; discussion 321-3. 2003
    ..The objective of this study was to determine the long-term outcome of patients with early HCC who would have been candidates for transplantation but were treated instead with partial hepatectomy...
  72. ncbi request reprint Surgery and ablative therapy for hepatocellular carcinoma
    Charles Cha
    Hepatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Gastroenterol 35:S130-7. 2002
    ..The rational application of the myriad of therapies to a patient with HCC is designed to maximize both quality of life and survival...
  73. ncbi request reprint Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, and Molecular Biology Program, Sloan Kettering Institute, New York, New York, 10021, USA
    Clin Cancer Res 9:3329-37. 2003
    ..The impact of KIT mutation in other regions, such as the extracellular or kinase domains, is not well-defined and fewer than 30 cases have been published to date...
  74. ncbi request reprint Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors
    William R Jarnagin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer 94:2040-6. 2002
    ....
  75. pmc Natural history of patients with subcentimeter pulmonary nodules undergoing hepatic resection for metastatic colorectal cancer
    Shishir K Maithel
    Department of Surgery, Division of Surgical Oncology, Emory University, Atlanta, GA, USA
    J Am Coll Surg 210:31-8. 2010
    ..CT imaging frequently detects subcentimeter pulmonary nodules (SPN) in patients undergoing resection of colorectal cancer liver metastases. Their clinical significance is unknown...
  76. pmc Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer
    Nancy E Kemeny
    Memorial Sloan Kettering Cancer Center, Weill Medical College, NY, USA
    J Clin Oncol 29:884-9. 2011
    ..Add systemic bevacizumab (Bev) to adjuvant hepatic arterial infusion (HAI) plus systemic therapy after liver resection to increase recurrence-free survival (RFS)...
  77. doi request reprint Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution
    Michael G House
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Am Coll Surg 210:744-52, 752-5. 2010
    ..This study analyzes factors associated with differences in long-term outcomes after hepatic resection for metastatic colorectal cancer over time...
  78. doi request reprint Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases
    Michael D'Angelica
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 18:1096-103. 2011
    ..Despite improvements in surgery and chemotherapy, most patients develop recurrence after hepatectomy for metastatic colorectal cancer. Data are lacking on the effect of these patterns on outcome...
  79. ncbi request reprint Impact of steatosis on perioperative outcome following hepatic resection
    David A Kooby
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Gastrointest Surg 7:1034-44. 2003
    ..Steatosis alone should not preclude aggressive hepatic resection for neoplasms when indicated; however, patients with marked steatosis undergoing large resections should still be approached with due caution...
  80. doi request reprint Analysis of the extent of resection for adenocarcinoma of the gallbladder
    Michael D'Angelica
    Hepatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg Oncol 16:806-16. 2009
    ..Major hepatic resections, including major hepatectomy and CBD excision, are appropriate when necessary to clear disease but are not mandatory in all cases...
  81. ncbi request reprint Autologous versus allogeneic transfusions: no difference in perioperative outcome after partial hepatectomy. Autologous transfusion on hepatectomy outcome
    James O Park
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, C897, New York, NY 10021, USA
    J Gastrointest Surg 11:1286-93. 2007
    ..In patients undergoing hepatic resection, autologous blood transfusion did not demonstrably improve perioperative outcome when compared to a matched cohort of patients receiving a similar number of allogeneic units...
  82. pmc The impact of margins on outcome after hepatic resection for colorectal metastasis
    Chandrakanth Are
    Hepatobiliary Division, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 246:295-300. 2007
    ..To analyze the impact of margin width on long-term outcome after hepatic resection for colorectal metastasis...
  83. pmc Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma
    William R Jarnagin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 241:703-12; discussion 712-4. 2005
    ..The current study compares outcome after resection of papillary hilar cholangiocarcinoma to that of the more common nodular-sclerosing subtype...
  84. ncbi request reprint Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation
    Cristina R Antonescu
    Department of Pathology, Sloan Kettering Institute, New York, New York, USA
    Clin Cancer Res 11:4182-90. 2005
    ..That acquired resistance to imatinib in GIST commonly occurs via secondary gene mutation in the KIT kinase domain has implications for strategies to delay or prevent imatinib resistance and to employ newer targeted therapies...
  85. ncbi request reprint Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site
    Cristina R Antonescu
    Departments of Pathology, Memorial Sloan Kettering Cancer Center, and Molecular Biology, Computational Biology Center, Sloan Kettering Institute, New York, New York 10021, USA
    Clin Cancer Res 10:3282-90. 2004
    ..We tested the hypothesis that the gene expression profile in GISTs might be related to KIT genotype and possibly to other clinicopathological factors...
  86. ncbi request reprint Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study
    Michael D'Angelica
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Ann Surg Oncol 14:759-65. 2007
    ..Perioperative bev is now commonly used in patients undergoing hepatic resection. Little is known, however, about the safety of perioperative bev use in the setting of hepatic resection...
  87. ncbi request reprint Hepatic follicular dendritic cell sarcoma without Epstein-Barr virus expression
    Ulises Torres
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Arch Pathol Lab Med 129:1480-3. 2005
    ..Based on our experience and a review of the published reports, we summarize the clinical and pathologic features of hepatic follicular dendritic cell sarcoma and its surgical management...
  88. ncbi request reprint Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastases
    Sam S Yoon
    Department of Surgery, Division of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Yawkey 7B 7926, 55 Fruit Street, Boston, Massachusetts 02114, USA
    Ann Surg Oncol 13:353-62. 2006
    ..Circulating angiogenic factors in patients with colorectal cancer liver metastases may promote tumor growth and contribute to liver regeneration after partial hepatectomy...
  89. doi request reprint A prospective randomized trial of acute normovolemic hemodilution compared to standard intraoperative management in patients undergoing major hepatic resection
    William R Jarnagin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, C 887, New York, NY 10065, USA
    Ann Surg 248:360-9. 2008
    ....
  90. ncbi request reprint Predicting the risk of perioperative transfusion for patients undergoing elective hepatectomy
    Camelia S Sima
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Surg 250:914-21. 2009
    ..To develop 2 instruments that predict the probability of perioperative red blood cell transfusion in patients undergoing elective liver resection for primary and secondary tumors...
  91. doi request reprint Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: initial results
    Constantinos T Sofocleous
    Section of Interventional Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room H 118, New York, NY 10065, USA
    Radiology 249:364-74. 2008
    ..To determine whether histopathologic and immunohistochemical features of tissue adherent to electrodes after radiofrequency (RF) ablation of liver malignancies can help predict local tumor progression (LTP)...
  92. ncbi request reprint Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome
    William R Jarnagin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:1152-60. 2006
    ..This clinicopathologic study characterizes differences in cell cycle-regulatory protein expression across the spectrum of BTA...
  93. ncbi request reprint Segment-oriented approach to liver resection
    K H Liau
    Hepatobiliary Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Surg Clin North Am 84:543-61. 2004
    ..The technique promotes tumor clearance while con-serving uninvolved parenchyma...
  94. ncbi request reprint Clinical/pathologic features and survival of patients with fibrolamellar-hepatocellular carcinoma (FLL-HCC): Data from the Fibrolamellar-Hepatocellular (FLL-HCC) Consortium
    C Ang
    Memorial Sloan Kettetring Cancer Center, New York, NY University of California, San Francisco, San Francisco, CA The Johns Hopkins Hospital, Baltimore, MD Memorial Sloan Kettering Cancer Center, New York, NY Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD The Johns Hopkins University School of Medicine, Baltimore, MD
    J Clin Oncol 29:4089. 2011
    ..4089 Background: FLL-HCC is rare and develops in young individuals of either gender in the absence of underlying liver disease. There are limited data on the demographics and outcome of FLL-HCC...
  95. pmc CT and MRI of primary and metastatic fibrolamellar carcinoma: a case series of 37 patients
    R K G Do
    1 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Br J Radiol 87:20140024. 2014
    ..Fibrolamellar carcinoma (FLC) is a rare disease, with limited radiographic reported information. We assessed the imaging patterns of primary and metastatic FLC...
  96. pmc Neutrophil IL-10 suppresses peritoneal inflammatory monocytes during polymicrobial sepsis
    Lee M Ocuin
    Hepatopancreatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Leukoc Biol 89:423-32. 2011
    ..In vitro experiments confirmed that monocyte suppression was mediated by neutrophil-derived IL-10. Thus, during septic peritonitis, neutrophils suppress peritoneal inflammatory monocytes through IL-10 and are dispensable for survival...
  97. pmc Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients
    Sharon M Weber
    Department of Surgery, Hepatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 235:392-9. 2002
    ..To evaluate the benefit of staging laparoscopy in patients with gallbladder cancer and hilar cholangiocarcinoma...
  98. ncbi request reprint Molecular mechanisms in hepatocellular carcinoma development
    Charles Cha
    Department of Surgery, Yale University School of Medicine, New Haven, CT, USA
    Best Pract Res Clin Gastroenterol 19:25-37. 2005
    ..It is not clear which events are critical in tumor initiation versus tumor progression. RNA expression arrays and proteomics hold promise to provide further clues about this common and complex cancer...
  99. ncbi request reprint Outcome of patients with fibrolamellar hepatocellular carcinoma
    Francesco Stipa
    Department of Surgery, San Giovanni Hospital, Rome, Italy
    Cancer 106:1331-8. 2006
    ..Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare variant of hepatocellular carcinoma, has distinct pathologic features, and typically occurs in young patients without underlying hepatitis or cirrhosis...
  100. ncbi request reprint Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases
    George Miller
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Coll Surg 205:231-8. 2007
    ..But the benefits of resection and appropriate selection criteria in patients who develop both hepatic and pulmonary metastases are ill defined...
  101. ncbi request reprint Diagnostic laparoscopy prior to planned hepatic resection for colorectal metastases
    Stephen R Grobmyer
    Department of Surgery, Division of Hepatobiliary Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Arch Surg 139:1326-30. 2004
    ..2) Preventing unnecessary celiotomy in these patients undergoing laparoscopy is associated with shorter hospital stays and earlier administration of systemic chemotherapy...

Research Grants2

  1. STI571 Therapy for Gastrointestinal Stromal Tumors
    Ronald DeMatteo; Fiscal Year: 2002
    ..The results are essential to advance our understanding of GIST biology and determine the therapeutic value and limitations of STI571. ..
  2. Natural Killer Dendritic Cells in Listeria Infection
    Ronald DeMatteo; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..